Invention Application
- Patent Title: CLINICAL CORRELATES OF IMMUNOTHERAPY EFFICACY
- Patent Title (中): 免疫疗效的临床相关性
-
Application No.: PCT/SG2016/050441Application Date: 2016-09-09
-
Publication No.: WO2017095324A1Publication Date: 2017-06-08
- Inventor: CONNOLLY, John , HOPKINS, Richard , TOH, Han Chong
- Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH , TESSA THERAPEUTICS PTE. LTD. , SINGAPORE HEALTH SERVICES PTE. LTD.
- Applicant Address: 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 SG
- Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH,TESSA THERAPEUTICS PTE. LTD.,SINGAPORE HEALTH SERVICES PTE. LTD.
- Current Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH,TESSA THERAPEUTICS PTE. LTD.,SINGAPORE HEALTH SERVICES PTE. LTD.
- Current Assignee Address: 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 SG
- Agency: SPRUSON & FERGUSON (ASIA) PTE LTD
- Priority: SG10201509979S 20151204
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/574 ; A61K35/17 ; A61P35/00
Abstract:
A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT, wherein the disease is preferably a disease caused or exacerbated by infection with Epstein-Barr virus (EBV), such as EBV-positive nasopharyngeal carcinoma (NPC). Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT, preferably EBV-positive NPC.
Information query